Articles from Verily

Verily, a precision health AI company, today announced a collaboration with NVIDIA to integrate NVIDIA’s AI technology stack into its Pre platform, which is used by health system, life science, payer, and government customers and partners to more efficiently develop and deploy AI across healthcare.

Verily, a precision health AI company, today announced the launch of a new consumer health app, Verily Me, that will be featured at HLTH USA 2025. Verily Me is designed to close gaps in care and enable people to stay informed and engaged in their health journey over time.

Verily today announced a multi-year strategic collaboration with UCHealth, the University of Colorado Anschutz, and RefinedScience to transform how data is used and care is delivered, supported by Verily’s deep domain expertise and built-for-purpose healthcare technology capabilities.

Today Verily, an Alphabet health data platform and AI company, announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to generate a comprehensive molecular dataset to advance Parkinson’s disease research.

Today, Verily, a precision health technology company, announced a significant expansion of its wastewater surveillance program into the United Kingdom through an exclusive partnership with Bangor University. This collaboration will leverage the university’s wastewater-based public health surveillance program capabilities and main testing lab. Bangor University’s wastewater monitoring capabilities are market leading in the U.K. for environmental bio-surveillance and the university’s lab serves as the research and development hub for the United Kingdom Health Security Agency (UKHSA).

Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka), a global pharmaceutical company, announces the launch of My Mental Health Journey, a longitudinal registry study that aims to advance research in depression and mental health. Verily Life Sciences LLC (Verily), a precision health technology company, will recruit participants and run the study.

Verily, an Alphabet precision health technology company, today announced the appointment of Bharat Rajagopal as Chief Revenue Officer. Rajagopal will join Verily’s leadership team and be responsible for the strategy and execution of all commercial revenue generating activities, including driving sales, business development, partnerships, and customer success to advance precision health.

Verily, an Alphabet precision health technology company, today announced the appointment of Myoung Cha as Chief Product Officer. Cha will join Verily’s leadership team to lead strategy and development across the company’s care (Verily Onduo), research (Verily Viewpoint), and products (Verily Numetric) portfolio as the company furthers its precision health strategy.

Georgiamune, a privately held, clinical stage biotechnology company, and Verily, an Alphabet precision health technology company, today announced a strategic partnership to advance novel therapeutics for patients with cancer.

Verily, an Alphabet precision health technology company, has launched Viewpoint Workbench, a new enterprise-grade platform to unify multimodal data and accelerate biomedical research.

Sosei Group Corporation ("Sosei Heptares"; TSE: 4565) and Verily, an Alphabet precision health technology company, today announced the successful validation and nomination of a first G-protein-coupled receptor (GPCR) target into early drug discovery for immune-mediated diseases with an initial indication focus of inflammatory bowel disease (IBD).

Verily, an Alphabet precision health technology company, today announced it was selected by the Centers for Disease Control (CDC) to support the agency’s National Wastewater Surveillance System (NWSS). The CDC launched NWSS in September 2020 to coordinate and build the nation’s capacity to track the presence of SARS-CoV-2 in wastewater samples collected across the country.

Verily, an Alphabet precision health technology company, and OneOncology, the national platform for independent oncology practices, have established a strategic partnership that will enable more efficient clinical trials.

Verily, an Alphabet precision health technology company, today announced the appointment of Andrew Trister, MD, PhD as Chief Scientific Officer. Dr. Trister will be responsible for leading the company’s population health initiatives and will provide expertise across Verily’s portfolio as the company furthers its precision health strategy.

Verily, an Alphabet precision health technology company, today announced the appointment of Laura O’Donnell as General Counsel.

Verily, an Alphabet company focused on precision health, today announced the appointment of Utpal Koppikar as Chief Financial Officer.

Verily, an Alphabet company focused on precision health, and the Crohn’s & Colitis Foundation, a non-profit organization dedicated to finding cures for Crohn’s disease and ulcerative colitis and to improving the quality of life of children and adults affected by these diseases, announced today an expanded strategic partnership. The collaboration will focus on building a longitudinal registry to accelerate research in Crohn’s disease and in ulcerative colitis, collectively known as inflammatory bowel disease (IBD).

Verily and Swiss Re today announced they have closed a transaction whereby Swiss Re exchanged its investment in Granular Insurance Company (“Granular”) for an equity stake in Verily. Granular is now wholly-owned by Verily.

Verily today announced a $1 billion dollar investment round led by Alphabet, that will be used to support the expansion of Verily’s businesses focused on precision health. Verily is also announcing new roles for the company’s top leadership.

Onduo by Verily, an Alphabet precision health company, announced today a strategic collaboration with Sword Health, the fastest-growing digital musculoskeletal (MSK) care provider, to offer complementary solutions to each company’s employer customers and their employees. This broadens employee access to a spectrum of virtual care benefits for chronic conditions, such as type 2 diabetes, hypertension, and mental health via Onduo’s solution, as well as care benefits for musculoskeletal pain via Sword’s.

Verily, an Alphabet company founded at the convergence of healthcare, data science and technology, today announced the opening of its new office in Dallas, Texas, which will focus on the maturation of the business, including scaling the company’s IT infrastructure and commercial organization. Verily is actively recruiting talent for highly skilled jobs with a focus on IT, Sales and Marketing, and Operations in Dallas.

Verily, an Alphabet company, today announced that its previously announced acquisition of SignalPath, a privately held company that makes clinical research software based in Raleigh, has successfully closed.

Mayo Clinic and Verily, an Alphabet company founded at the convergence of health care, data science and technology, today announced a strategic two-year collaboration. This collaboration focuses on the development of a digital point-of-care resource of vetted knowledge to support an individualized approach to patient care. This modular, evidence-based decision support solution, will provide contextualized and validated knowledge on disease management, care guidelines and treatment to help clinician's make decisions.

Verily, an Alphabet company, and SignalPath today announced that they have entered into an agreement in which Verily will acquire SignalPath, a privately held company based in Raleigh that has developed the SignalPath platform, a clinical trial management system (CTMS) that improves the ease, quality and efficiency of conducting clinical research at study sites.

Verily, an Alphabet company, and Colgate-Palmolive, the global leader in oral care, today announced a strategic collaboration to advance oral health research. Under the agreement, Colgate's Dental Clinical Team will partner with Verily to conduct an innovative oral health study as part of Verily’s ongoing Baseline Health Study that will aim to improve understanding of connections between oral health and overall human health.

Verily, an Alphabet company founded at the convergence of healthcare, data science and technology, today announced the opening of its new research and development center in Israel. The Verily Israel team will focus on applying artificial intelligence (AI) techniques to important biomedical problems, including applications in endoscopy, minimally invasive surgery and other imaging modalities.

Verily, an Alphabet company, today announced the appointment of Amy Abernethy, M.D., Ph.D. as President of Verily’s clinical research business. Verily’s clinical research started with the Baseline program, a suite of studies using patient-centric tools for research data collection. Today’s announcement foreshadows Verily’s planned expansion into a full-scale clinical evidence generation platform supporting a broad range of clinical trials and real-world evidence (RWE) studies. As President of this business unit, Dr. Abernethy will oversee this overall product vision and Verily’s related clinical research portfolio.

Verily, an Alphabet company, today announced the appointment of Kerrie Peraino to the role of Chief People Officer. Peraino joins Verily from Google, where she was Vice President, People Operations. Peraino will be responsible for all People Operations activities, including talent and leadership development, talent acquisition, learning, compensation and benefits, diversity and inclusion and employee relations.

Verily, an Alphabet company, today announced the appointment of Lisa Greenbaum to the newly-created role of chief revenue officer. Greenbaum will be responsible for all commercial activities across the organization including sales, business development, alliance management, sales operations and other sales-related activities and teams. Greenbaum’s appointment builds upon Verily’s January 2021 appointment of Andreas “Drew” Panayiotou as chief marketing officer.